BioStem Technologies Prepares to Uplist to Senior Exchange

New York, April 25, 2024 - PRISM MarketView - BioStem Technologies (OTC: BSEM) has completed a two year audit as part of its preparations for uplisting to a senior stock exchange. The company announced today that it anticipates its uplisting will help to further validate BioStem’s market position, attract a broader investor base, and enhance shareholder value.

BioStem Technologies reported remarkable growth in 2023, with a year-over-year net revenue increase of 1,355% to $11.5 million in the fourth quarter, with the gross profit margin reaching 95% of revenue, up from 84% the previous year. The company attributed this strong progress to the successful commercial launch into the private office setting of AmnioWrap2, an innovative placental-derived allograft product designed to address a broad spectrum of wound applications.

BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioRetain® processing method. BioRetain® has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB”). These systems and procedures are established per current Good Tissue Practices (“cGTP”) and current Good Manufacturing Processes (“cGMP”). Our portfolio of quality brands includes AmnioWrap2®, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. Each BioStem Technologies placental allograft is processed at the Company’s FDA registered and AATB accredited site in Pompano Beach, Florida. For more information, please visit: http://www.biostemtechnologies.com

BioStem Technologies (OTC: BSEM) is featured on PRISM Emerging MedDevices Index 

Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on Twitter.

PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.

PRISM MarketView
info@prismmarketview.com
646-863-6341